Figure: Overall survival with pembrolizumab at two doses vs. docetaxel in the population with TPS ≥1 % (KEYNOTE-010)
10.02.2016 | Onkologie | Online-Artikel
10.02.2016 | Onkologie | Online-Artikel
Figure: Overall survival with pembrolizumab at two doses vs. docetaxel in the population with TPS ≥1 % (KEYNOTE-010)